Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04292899 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,891
- Enrollment target
NCT04292899 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 4,891 participants.
The verdict
NCT04292899, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,891 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical status assessed by a 7-point ordinal scale on Day 14.
Interventions
- DRUG Standard of Care
- DRUG Remdesivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,891 participants |
| Start Date | 2020-03-06 |
| Est. Completion | 2020-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04292899
The ClinicalTrials.gov registry entry for NCT04292899 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,891 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT04292899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04292899 about?
NCT04292899 is a clinical study titled "Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)". The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical status assessed by a 7-point ordinal scale on Day 14.
What is the current status of trial NCT04292899?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,891 participants. The study started on 2020-03-06. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT04292899?
The interventions under investigation include: Standard of Care (DRUG), Remdesivir (DRUG).
Who is sponsoring clinical trial NCT04292899?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.